This observation that mice treated with anti-TREM2 antibody showed reduced tumor burden, suggests that individuals with highly immunosuppressive TREM2 + TAM-rich TME, like those with ovarian cancer, could benefit from administration of an antibody targeting TREM2-expressing TAMs [177]. Here, TREM2 is linked to neoplasm.